scorecardresearch
Monday, Dec 05, 2022

Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

The Lupin Ltd. pharmaceutical plant stands in Salcette, Goa, India, on Friday, Feb. 7, 2014. (Photographer: Dhiraj Singh/Bloomberg)

Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name ‘Covihalt’ for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet.

Lupin President – India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.

Subscriber Only Stories
UPSC Key- December 5, 2022: Why you should read ‘Iran’s morality police’ ...Premium
UPSC Essentials | Key terms of the past week with MCQsPremium
Amid Bengaluru gangrape investigation, lens on Rapido: how does the bike ...Premium
When Bhagat Singh got a pat from Bal Gangadhar TilakPremium

On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name ”FluGuard” for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.

Shares of Lupin were trading 0.32 per cent higher at Rs 943.70 apiece on BSE.

First published on: 05-08-2020 at 01:21:44 pm
Next Story

Tamil Nadu TN Board SSLC results to be declared today

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement
close